(Q51490845)

5 April 2018

title

A new sustained-release preparation of human growth hormone and its pharmacokinetic, pharmacodynamic and safety profile. (English)

1 reference

5 April 2018

1 reference

1 reference

Andreas Jostel

1

1 reference

5 April 2018

Annice Mukherjee

2

1 reference

5 April 2018

Jan Alenfall

3

1 reference

5 April 2018

Linda Smethurst

4

1 reference

5 April 2018

Stephen M Shalet

5

1 reference

5 April 2018

publication date

1 May 2005

1 reference

5 April 2018

published in

Clinical Endocrinology

1 reference

5 April 2018

volume

62

1 reference

5 April 2018

issue

5

1 reference

5 April 2018

page(s)

623-627

1 reference

5 April 2018

Influences on quality of life in GH deficient adults and their effect on response to treatment

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02271.X

The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02271.X

Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02271.X

Clinical pharmacological aspects of growth hormone administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02271.X

Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults: I. Effects on insulin-like growth factor-I (IGF-I), GH and IGF binding proteins, and glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02271.X

A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02271.X

Long-Term Effects of Continuous Subcutaneous Infusion Versus Daily Subcutaneous Injections of Growth Hormone (GH) on the Insulin-Like Growth Factor System, Insulin Sensitivity, Body Composition, and Bone and Lipoprotein Metabolism in GH-Deficient Adu

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2005.02271.X

10.1111/J.1365-2265.2005.02271.X

21 January 2018

Identifiers

DOI

1 reference

5 April 2018

1 reference

5 April 2018